Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.76 EUR
Change Today -0.027 / -3.42%
Volume 362.1K
TIG On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 5:29 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

tigenix nv (TIG) Snapshot

Open
€0.80
Previous Close
€0.79
Day High
€0.80
Day Low
€0.76
52 Week High
07/23/15 - €0.85
52 Week Low
10/16/14 - €0.48
Market Cap
122.4M
Average Volume 10 Days
928.1K
EPS TTM
€-0.07
Shares Outstanding
160.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TIGENIX NV (TIG)

Related News

No related news articles were found.

tigenix nv (TIG) Related Businessweek News

No Related Businessweek News Found

tigenix nv (TIG) Details

TiGenix NV, a biopharmaceutical company, develops and commercializes cell therapy products. Its pipeline is based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. The company is developing Cx601, which is in Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease; Cx611, an allogeneic eASC that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis and Phase Ib trail for severe sepsis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It has operations in Belgium, the Netherlands, Spain, and internationally. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

49 Employees
Last Reported Date: 03/27/15
Founded in 2000

tigenix nv (TIG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €476.6K
Compensation as of Fiscal Year 2014.

tigenix nv (TIG) Key Developments

Dirk Buscher and Jose Terencio Resign from TiGenix NV Board of Directors, Effective July 31, 2015

TiGenix NV announced that Dirk Büscher and José Terencio resigned from their position as board member, effective as of July 31, 2015. Dirk Büscher and José Terencio are the CEO and COO respectively of Gri-Cel SA.

TiGenix Submits Application for Approval of Investigational Crohn's Disease Treatment Cx601

TiGenix announced that it has begun a marketing application process for the late-stage investigational candidate Cx601, treating complex perianal fistulas in patients with Crohn's disease. TiGenix has submitted a letter of intent to the European Medicines Agency (EMA), which is a necessary precondition before a formal marketing authorisation application (MAA) can be made. The usual timescale for submitting a formal MAA means TiGenix is likely to file after January 2016. Cx601 is an orphan-designated product and therefore is also eligible for the EMA's centralised approval procedure. The centralised approval procedure would potentially allow TiGenix to make a single market authorisation application for Cx601 in all European Union member countries, provided of course that the company secures marketing authorisation in the first place. The drug is currently completing a Phase III randomised, double-blind, placebo-controlled trial, the results of which are expected in the third quarter.

TiGenix NV Announces the Results of Its Phase I Sepsis Challenge Trial of Cx611 Confirm Safety and Tolerability

TiGenix NV announced that the results of its Phase I sepsis challenge trial of Cx611 confirm safety and tolerability. The results of this Phase I proof of principle study demonstrate the favorable safety and tolerability profile of Cx611, which is consistent with previous study in patients with rheumatoid arthritis. Cx611 is an intravenously-administered product of allogeneic expanded adipose-derived stem cells (eASCs). Its efficacy in significantly reducing mortality has been demonstrated in several animal models of sepsis through a combination of reduced inflammation, production of anti-microbial effectors, and increased phagocytosis. This Phase I trial was a proof of principle study designed to demonstrate the safety and the ability of Cx611 in modifying the inflammatory response in healthy volunteers challenged with a bacterial endotoxin. The trial was a placebo-controlled, parallel group study in which 32 healthy male volunteers were randomised to receive Cx611 (at 3 doses) or placebo in a ratio of 3:1 and followed for 24 hours.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIG:BB €0.76 EUR -0.027

TIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Vericel Corp $3.39 USD +0.03
View Industry Companies
 

Industry Analysis

TIG

Industry Average

Valuation TIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.2x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIGENIX NV, please visit www.tigenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.